Roche's Genentech is sticking with Orionis Biosciences, handing over $105 million upfront as part of its second deal with the molecular glue biotech. The latest multiyear collaboration will be focused ...

Orionis Biosciences has announced a multi-year partnership with Roche’s Genentech, focusing on the discovery and development of small-molecule monovalent glue medicines for difficult targets in ...

Novartis has entered into a four-year research collaboration with Orionis Biosciences. The agreement tasks Orionis with applying its technologies to “historically elusive targets” in multiple ...

BOSTON & GHENT, Belgium--(BUSINESS WIRE)--Orionis Biosciences, a privately held, clinical-stage life sciences company focused on the rational discovery and development of drug modalities with induced ...

Orionis Biosciences, a privately held company, announced a second multi-year collaboration with Genentech, a member of the Roche Group (OTCQX:RHHBY) on Wednesday. The goal of this partnership is to ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Roche’s Genentech unit will pay privately held Orionis ...

Genentech signed onto a $47 million partnership with biotech Orionis Biosciences to focus on discovering novel small molecule therapies across various therapeutic areas, including cancer and ...

BOSTON & GHENT, Belgium--(BUSINESS WIRE)--Orionis Biosciences, a life sciences company pioneering innovation of highly selective and tunable therapeutics for cancer and beyond, today announced it has ...

FU Orionis is the prototype of a class of novalike variables that undergo some of the most extreme variability seen in pre-main sequence stars. FU Orionis and its kin characteristically flare by ...